SCHEDULE: Lantheus Holdings Sells Perspective Therapeutics Shares

Lantheus Holdings, Inc. and its subsidiaries have reported the sale of over 236,000 shares of Perspective Therapeutics, Inc. common stock, reducing their beneficial ownership to 10.0%.

Summary

• Lantheus Holdings, Inc., along with its subsidiaries Lantheus Medical Imaging, Inc. and Lantheus Alpha Therapy, LLC (collectively, the 'Reporting Persons'), have filed an amendment to their Schedule 13D.
• This amendment reports the dilution of their beneficial ownership in Perspective Therapeutics, Inc. (the 'Issuer') and the disposition of shares.
• As of September 3, 2026, the Reporting Persons beneficially own 11,440,513 shares of Common Stock, representing 10.0% of the Issuer's outstanding shares.
• This percentage is based on 114,151,663 shares outstanding as of August 5, 2026, adjusted for a 1-for-10 reverse stock split.
• The Reporting Persons are authorized to sell their shares subject to market conditions through various transaction types.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the reported sales of shares by the reporting persons, indicating a potential reduction in their stake and confidence, despite the overall ownership percentage remaining at 10.0%.

Positives

• The Reporting Persons continue to hold a significant stake, representing 10.0% of the Issuer's outstanding common stock.
• The filing is an amendment to a previous filing, indicating ongoing disclosure and transparency.
• The Reporting Persons are authorized to sell shares, providing flexibility in managing their investment.

Negatives

• The Reporting Persons sold a total of 236,826 shares of Common Stock between August 31, 2026, and September 3, 2026.
• Specific sales include 78,145 shares on August 31, 2026, 35,769 shares on September 1, 2026, 42,129 shares on September 2, 2026, and 80,783 shares on September 3, 2026.
• The average sales price per share ranged from approximately $3.1058 to $3.143 during these sales.

Risks

• The disposition of shares by the Reporting Persons could indicate a reduced confidence in the Issuer's future performance or a strategic shift in their investment.
• Further sales could potentially impact the Issuer's stock price, especially if conducted in large volumes.

Future Outlook

The Reporting Persons are authorized to sell their shares of Common Stock subject to certain market conditions from time to time, through various transaction methods.

Management Comments

• Shares reported as beneficially owned represent shares directly held by Lantheus Alpha Therapy, LLC ('Lantheus Alpha'), a wholly owned direct subsidiary of Lantheus Medical Imaging, Inc. ('Lantheus Medical').
• Lantheus Medical is the sole member of Lantheus Alpha and a wholly-owned subsidiary of Lantheus Holdings, Inc. ('Lantheus Holdings').
• Lantheus Holdings, Lantheus Medical and Lantheus Alpha may each be deemed to have shared voting and dispositive power over all of the shares of Common Stock held by Lantheus Alpha.
• The number of shares of Common Stock disclosed in this Statement have been adjusted to reflect the Reverse Stock Split.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are typically made by investors who acquire a significant stake (over 5%) in a public company. Amendments often report changes in ownership, strategic intentions, or material events. The sales reported here by Lantheus Holdings, a company involved in diagnostic medical imaging and radiotherapeutics, suggest a potential rebalancing of their investment portfolio or a realization of gains.

Stakeholder Impact

• Shareholders may view the sales by a significant holder as a negative signal, potentially leading to downward pressure on the stock price.
• The reduction in ownership by Lantheus Holdings could alter the dynamics of significant shareholder influence on the Issuer's strategic decisions.

Next Steps

• The Reporting Persons may continue to sell shares of Common Stock subject to market conditions.
• Further amendments to the Schedule 13D may be filed if there are material changes in beneficial ownership or intentions.

Key Dates

Recommendation

While the sales by Lantheus Holdings are a negative indicator, they still retain a 10.0% stake. The filing does not provide enough information to warrant a strong buy or sell recommendation, suggesting a 'hold' position to observe further developments and the Issuer's performance.

Keywords

Schedule 13D, Beneficial Ownership, Stock Sale, Dilution, Lantheus Holdings, Perspective Therapeutics, Common Stock, Investment Agreement